|
Clarymist Lipisomal Eye Spray 10ml:
£12.90
IN STOCK
ORDER
A new innovative dry eye therapy, Clarymist is a class 2a medical device that is sprayed onto a
CLOSED
eye.
Very frequently evaporation
of the tear liquid is the main cause of liquid loss in patients with dry
eye syndrome. The cause of the dry eye is therefore not an
insufficient tear flow but rather a fast evaporation due to disturbances
of the lipid tear layer. Most
over-the-counter eye drops available today supplement the aqueous layer
only. These drops do nothing to restore the protective lipid layer,
leaving patients reaching for their eye drops time and again throughout
the day because the drops only provide short-term relief. Instead of simply adding more tears to
the eye surface, Clarymist ™ eye spray adopts the more
sophisticated approach of restabilising the existing tear film and so
allowing the patient’s natural tears to re-establish. Clarymist
™ simply sprays onto
the closed eyelid and by migration from the eye lashes and lid margin,
it provides the lipids that restore stability to the tear film,
in a
similar way to those of normal meimbomian gland secretions.
Current models of the lipid phase
differentiate between an outer non-polar layer and an inner, thin polar
layer that borders the aqueous phase.
The outer, non-polar layer of the lipid
phase protects tear liquid from evaporation and is composed of wax
ester, sterolester, triglycerides, and further lipids.
The inner polar layer forms an
interface between the non-polar lipids and the aqueous phase and is
responsible for the functional stability of the lipid phase. It is
composed of interface molecules that possess both a hydrophilic as well
as a lipophilic group, and these are known as amphiphilic molecules.
Phospholipids are amphiphilic molecules
– their non-polar fatty acids interact with the lipids, and the polar
headgroups interact with the aqueous phase. 70% of the polar lipids of
the tear film are phospholipids.
Dry eye syndrome caused by evaporation
is thought to be due to an anomaly of these polar lipids because a
deficiently structured polar layer adversely influences the non-polar
layer of the lipid phase and leads to increased evaporation.
The key ingredients that Clarymist ™
eye spray delivers are phospholipids, the vital amphiphilic building
blocks of the interfacing polar layer. The specific phospholipid that
Clarymist ™ supplies is phosphatidylcholine, which is
also the most prevalent phospholipid secreted naturally. The supplied
phospholipids help restore the polar layer, resulting in restabilisation
of the lipid phase and a reduction in evaporation of the tear film. The
natural consequence of this is alleviation of the patient’s dry eye
symptoms.
Clinical Sudies
A study of 382 dry eye sufferers was performed in Stuttgart between
August 2003 and May 2004 to test the effectiveness of Clarymist
™ eye spray – at that time marketed in Germany as “Tears Again”
tm. The methodology for the trial was ‘double blind’ - neither the clinicians nor the
volunteer users knew who was taking the real product and who was taking
a placebo control. It was also ‘crossover’, which means the whole
experiment was repeated with the control and treatment groups reversed.
These precautions eliminate the common experimental errors of observer
bias, subject bias and group difference, and assure highly reliable
findings.
Clearly
Demonstrated Effectiveness
of Clarymist ™
At the end of the trial, parameters such as LIPCOF, BUT, and Schirmer
were all significantly superior in the treatment group compared to the
control group. Other effects included an unexpected remarkable reduction of inflammation of the margins of the eyelid in patients with
chronic blepharitis. Out of 114 patients with inflammation of the eyelid edges,
only 30 still suffered symptoms after 4 weeks of treatment. The main
liposome component, phosphatidylcholine, has been shown to have antioxident properties and
is active against a multitude of chemical toxins. Every patient was of the opinion that using
Clarymist ™ eye spray is more straightforward and more pleasant
than tear substitute eye drops .
These outstanding results achieved were
published in the leading German Ophthalmic Journal. (Klin Monatsbl
Augenheilkunde 2004;221: 825-836)
The information on this page is
supported by the clinical study report: ‘A new Therapy Concept with a
Liposome Eye Spray for the Treatment of Dry Eye’ by Sven Lee MD PhD,
Sabine Dausch, Günther Maierhofer, Dieter Dausch, MD PhD, published in
Klin Monatsbl Augenheilkunde 2004;221: 825-836
|
CLARYMIST LIPISOMAL SPRAY
